Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Slamon

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Acquired Immune Deficiency Syndromes|January 1, 1988
Prevalence of HTLV-I and HIV infection among white parenteral drug abusersJ B Glaser, P Coleman, D Slamon, et al.
Cancer Research|April 1, 1992
Radiolabeled antibody targeting of the HER-2/neu oncoproteinK De Santes, D Slamon, S K Anderson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1988
Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasiaJ T Norman, R E Bohman, G Fischmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancerG Konecny, M Untch, A Pihan, et al.
Breast Cancer Research and Treatment|September 20, 2001
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samplesG Konecny, M Untch, D Slamon, et al.
Cancer Research|December 15, 1990
Frequency and structure of p53 rearrangements in human osteosarcomaC W Miller, A Aslo, C Tsay, et al.
Oncogene|May 18, 1999
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersM Pegram, S Hsu, G Lewis, et al.
Breast Cancer Research and Treatment|January 5, 2002
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancerG Konecny, M Fritz, M Untch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1991
PET cancer evaluations with FDGR A Hawkins, C Hoh, M Dahlbom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Statistical controversies in clinical research: statistical significance-too much of a good thing …M Buyse, S A Hurvitz, F Andre, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Acquired Immune Deficiency Syndromes|January 1, 1988
Prevalence of HTLV-I and HIV infection among white parenteral drug abusersJ B Glaser, P Coleman, D Slamon, et al.
Cancer Research|April 1, 1992
Radiolabeled antibody targeting of the HER-2/neu oncoproteinK De Santes, D Slamon, S K Anderson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1988
Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasiaJ T Norman, R E Bohman, G Fischmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancerG Konecny, M Untch, A Pihan, et al.
Breast Cancer Research and Treatment|September 20, 2001
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samplesG Konecny, M Untch, D Slamon, et al.
Cancer Research|December 15, 1990
Frequency and structure of p53 rearrangements in human osteosarcomaC W Miller, A Aslo, C Tsay, et al.
Oncogene|May 18, 1999
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersM Pegram, S Hsu, G Lewis, et al.
Breast Cancer Research and Treatment|January 5, 2002
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancerG Konecny, M Fritz, M Untch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1991
PET cancer evaluations with FDGR A Hawkins, C Hoh, M Dahlbom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Statistical controversies in clinical research: statistical significance-too much of a good thing …M Buyse, S A Hurvitz, F Andre, et al.
Pageof 5